Meeting NewsVideo

VIDEO: Mitro updates Roclatan studies, Aerie financing

NEWPORT BEACH, Calif. ― At the OCTANe Ophthalmology Technology Summit here, Tom Mitro, president and COO of Aerie Pharmaceuticals, discusses the importance of meeting the needs of customers, gives an update on the latest phase 3 studies of Roclatan, which is a combination of Rhopressa and latanoprost, and talks about the company’s latest round of funding.

NEWPORT BEACH, Calif. ― At the OCTANe Ophthalmology Technology Summit here, Tom Mitro, president and COO of Aerie Pharmaceuticals, discusses the importance of meeting the needs of customers, gives an update on the latest phase 3 studies of Roclatan, which is a combination of Rhopressa and latanoprost, and talks about the company’s latest round of funding.

    See more from OCTANe Ophthalmology Technology Summit